This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Analysts' Actions: AMTD CLF GMCR MAR UAL

US Airways (LCC) was downgraded at J.P. Morgan to neutral. See limited upside potential, even with an expected UAL merger, J.P. Morgan said.

Marriott International (MAR - Get Report) was initiated at BMO Capital Markets with a market perform rating. $41 price target. North America is not a bad place to be, BMO said.

Nektar Therapeutics (NKTR) was initiated at Lazard Capital Markets with a buy rating. $15 price target. A bounty of attractive late stage programs, Lazard Capital Markets said.

Pharmacyclics (PCYC) was initiated at Credit Suisse with an outperform rating. $79 price target. Most derisked pure play in oral lymphoma/leukemia drug class, Credit Suisse said.

Patterson (PDCO) was downgraded at Goldman Sachs from neutral to sell. Company will likely be hurt by lower demand for high-tech dental equipment, Goldman said.

Petrologistics (PDH) was upgraded at Citigroup to buy from neutral. $17 price target. Elevated propane to propylene spread seems sustainable given warm weather, Citigroup said.

PDL Biopharma (PDLI) was downgraded at Credit Suisse from neutral to underperform. Valuation call, based on a $6 price target, Credit Suisse said.

Principal Financial Group (PFG) was downgraded at Sterne Agee to neutral from buy. Valuation call, Sterne Agee said.

Regeneron Pharmaceuticals (REGN) was downgraded at Jefferies downgraded to hold from buy. Limited upside on Eylea, Jefferies said.

Sirona Dental (SIRO) was downgraded at Goldman Sachs from buy to neutral. Valuation call, based on a $67 price target, Goldman Sachs said.

Symantec (SYMC) was upgraded at Morgan Stanley to overweight. $25 price target. Visibility is improving, and the company offers the best risk/reward in the industry, Morgan Stanley said.

United Continental (UAL - Get Report) was downgraded at J.P. Morgan to neutral. Valuation call, based on a $30 price target, J.P. Morgan said.

Vantiv (VNTV) was initiated with a neutral rating at UBS. $22 price target. Attractive secular exposure, but fully valued shares, UBS said.

Vertex Pharmaceuticals (VRTX) was downgraded at Lazard Capital Markets to neutral. Company is likely facing a transition year, Lazard Capital Markets said.

Watsco (WSO) was downgraded at Robert Baird from outperform to neutral. Valuation call, based on a $77 price target, Robert Baird said.


Apple (AAPL) estimates, target reduced at Nomura. Shares of AAPL now seen reaching $530. Estimates also cut, given lower expected iPhone sales. Neutral rating.

Caterpillar (CAT) target raised at Credit Suisse to $124, according to Credit Suisse. Survey suggests that dealers are meeting sales forecasts. Outperform rating.

Dell (DELL) target raised at Jefferies to $13, Jefferies said. LBO is a possibility. Hold rating.

Rock Tenn (RKT) cut from Conviction Buy List at Goldman. Valuation call, based on an $83 price target.

St. Jude Medical (STJ) numbers raised at Jefferies. Shares of STJ now seen reaching $39, Jefferies said. Estimates also raised on ending of near- term pressure from Riata/Durata. Hold rating.

>To submit a news tip, email:


Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AMTD $36.90 -0.38%
CLF $6.72 -0.59%
GMCR $130.17 -0.53%
MAR $83.91 -1.08%
UAL $69.00 3.28%


DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs